February 2, 2022
Life Sciences
  • Moderna Inc. began testing an experimental HIV vaccine based on its mRNA technology. The company plans to monitor 56 HIV-negative adults in the U.S. for six months in the Phase 1 clinical trial. Previous efforts to develop HIV vaccines have failed, and the illness still causes hundreds of thousands of deaths annually across the globe. (Article here)